Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes

Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes

The randomized, controlled clinical trial investigate the efficacy and safety of vildagliptin added to continuous subcutaneous insulin infusion in uncontrolled type 2 diabetes

Inclusion Criteria:

• T2DM
• 30≤ age≤70 years old
• BMI 18.0-28.0 Kg/m2
• HbA1c ≥8.5%
• Negtive GAD、ICA、IAA
• Patients do not use antihyperglycemia drugs
• Patients use antihyperglycemia drugs for ≥8 weeks(exclusion of DPP-4 inhibitors and GLP-1 receptor agonist)

Exclusion Criteria:

• T1DM,GDM
• Congestive heart failure (New York Heart Association Functional Classification III-IV)
• ALT or AST> 2 times above normal,GFR <50ml/min
• Severe infection in the previous 3 months
• Severely acute or chronic diabetic complications
• Patients who were taking medications,known to affect glycaemic control, such as glucocorticoids(aside from antidiabetic medications)
• History of pancreatitis
• Trauma or patients operating at a scheduled time
• Any mental health condition